A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity
This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.
• Male or female (sex at birth).
• Age at the time of signing the informed consent:
‣ For Part A:18-55 years (both inclusive)
⁃ For Part B and Part C: 18-65 years (both inclusive)
• Body Mass Index (BMI) at screening (overweight should be due to excess adipose tissue, as judged by the investigator):
‣ For Part A: 27.0-39.9 kilogram per square meter(kg/m\^2) (both inclusive)
⁃ For Part B and Part C:
• Greater than or equal to (≥) 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity (e.g. hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease), or
∙ Greater than or equal to (≥) 30.0 kg/m\^2
• Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as-judged by the investigator.
• Willingness to obtain a high weight loss (greater than \[\>\] 25 percent \[%\]).